NCT02756858已完成2 期
An Extension Study of ANAVEX2-73 in Patients With Mild to Moderate Alzheimer's Disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 21
- 试验地点
- 5
- 主要终点
- Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
研究概览
简要总结
This open label extension study is designed to provide continued access to ANAVEX 2-73 for eligible subjects with mild to moderate Alzheimer's Disease who have previously participated in the Anavex sponsored study ANAVEX2-73-002.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 55 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Previous exposure to ANAVEX2-73 via participation in Phase 2a Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 12-Month Open Label Follow-Up Period (ANAVEX2-73-002)
排除标准
- •Have not previously participated Phase 2a Study of ANAVEX2-73 Adaptive-Trial-Design With Repeated Doses, MTD Finding, Pharmacodynamic and Bioavailability Evaluation in Patients With Mild to Moderate Alzheimer's Disease With a 12-Month Open Label Follow-Up Period (ANAVEX2-73-002)
研究组 & 干预措施
ANAVEX2-73 Oral as assigned in ANAVEX2-73-002
Experimental
干预措施: ANAVEX2-73 (Drug)
结局指标
主要结局
Number of participants with treatment-related adverse events as assessed by CTCAE v4.0
时间窗: Up to 208 weeks
Safety
次要结局
- Score from MMSE (Mini-mental state examination score)(Baseline; Weeks: 13, 26, 39, 52, 65, 78, 91, 104, 117, 130, 143, 156, 169, 182, 195, 208)
- HAM-D Score (Hamilton Psychiatric Rating Scale for Depression)(Baseline; Weeks: 13, 26, 39, 52, 65, 78, 91, 104, 117, 130, 143, 156, 169, 182, 195, 208)
- Score from ADCS-ADL (Alzheimer's Disease Co-operative Study - Activities of Daily Living Inventory)(Baseline; Weeks: 13, 26, 39, 52, 65, 78, 91, 104, 117, 130, 143, 156, 169, 182, 195, 208)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
2 期
OLE of Phase 2b/3 Study ANAVEX2-73-AD-004Alzheimer DiseaseNCT04314934Anavex Life Sciences Corp.300
已完成
2 期
OLE Study for Patients With Parkinson's Disease With Dementia Enrolled in Study ANAVEX2-73-PDD-001Parkinson Disease DementiaNCT04575259Anavex Life Sciences Corp.132
已完成
2 期
Open Label Extension Study of AMX0035 in Patients With ALSAmyotrophic Lateral SclerosisALSNCT03488524Amylyx Pharmaceuticals Inc.90
终止
2 期
A Study to Allow Continued Dosing and/or Follow-up of Patients Who Have Had Previous Exposure to PoziotinibNSCLCBreast CancerNCT03744715Spectrum Pharmaceuticals, Inc7
已完成
2 期
Safety and Tolerability of AIN457 in Adults (18-65 Years) With Moderate to Severe Ankylosing SpondylitisAnkylosing SpondylitisNCT01109940Novartis Pharmaceuticals39